These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 11281951

  • 1. Hyperprolactinaemia induced by risperidone.
    Chung YC, Eun HB.
    Int J Neuropsychopharmacol; 1998 Jul; 1(1):93-94. PubMed ID: 11281951
    [Abstract] [Full Text] [Related]

  • 2. Risperidone (Risperdal): clinical experience with a new antipsychosis drug.
    Keks NA, Culhane C.
    Expert Opin Investig Drugs; 1999 Apr; 8(4):443-52. PubMed ID: 15992090
    [Abstract] [Full Text] [Related]

  • 3. [Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone].
    Niemegeers CJ, Awouters F, Janssen PA.
    Encephale; 1990 Apr; 16(2):147-51. PubMed ID: 1693560
    [Abstract] [Full Text] [Related]

  • 4. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T, Duffy L, O'brien E, Matsumoto I, Dedova I.
    Behav Brain Res; 2006 Aug 10; 171(2):286-94. PubMed ID: 16697060
    [Abstract] [Full Text] [Related]

  • 5. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF.
    J Pharmacol Exp Ther; 1988 Feb 10; 244(2):685-93. PubMed ID: 2450200
    [Abstract] [Full Text] [Related]

  • 6. Central 5-HT2 antagonists: A preclinical evaluation of a therapeutic potential.
    Meert TF, Awouters F.
    Acta Neuropsychiatr; 1990 Dec 10; 2(4):101-9. PubMed ID: 26952556
    [Abstract] [Full Text] [Related]

  • 7. Extrapyramidal side effects and tolerability of risperidone: a review.
    Owens DG.
    J Clin Psychiatry; 1994 May 10; 55 Suppl():29-35. PubMed ID: 7520906
    [Abstract] [Full Text] [Related]

  • 8. Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
    Jacobsen FM.
    J Clin Psychiatry; 1995 Sep 10; 56(9):423-9. PubMed ID: 7545159
    [Abstract] [Full Text] [Related]

  • 9. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
    Janssen PA, Awouters FH.
    Arzneimittelforschung; 1994 Mar 10; 44(3):269-77. PubMed ID: 7514873
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA, Awouters FH, Meert TF, Schellekens KH, Niemegeers CJ, Janssen PA.
    J Pharmacol Exp Ther; 1992 Jan 10; 260(1):146-59. PubMed ID: 1370538
    [Abstract] [Full Text] [Related]

  • 11. Sertindole: safety and tolerability profile.
    Kasper S.
    Int J Psychiatry Clin Pract; 2002 Jan 10; 6(1):27-32. PubMed ID: 24931887
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
    Möller HJ, Pelzer E, Kissling W, Riehl T, Wernicke T.
    Pharmacopsychiatry; 1991 Nov 10; 24(6):185-9. PubMed ID: 1725925
    [Abstract] [Full Text] [Related]

  • 13. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
    Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T.
    Synapse; 2002 Oct 10; 46(1):32-7. PubMed ID: 12211096
    [Abstract] [Full Text] [Related]

  • 14. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A.
    Clin Neurol Neurosurg; 2005 Oct 10; 107(6):497-508. PubMed ID: 15922506
    [Abstract] [Full Text] [Related]

  • 15. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC, Lung FW, Chong MY.
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar 10; 28(2):285-90. PubMed ID: 14751424
    [Abstract] [Full Text] [Related]

  • 16. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A.
    Dan Med Bull; 2000 Jun 10; 47(3):151-67. PubMed ID: 10913983
    [Abstract] [Full Text] [Related]

  • 17. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
    Holzer L, Eap CB.
    J Clin Psychopharmacol; 2006 Apr 10; 26(2):167-71. PubMed ID: 16633146
    [Abstract] [Full Text] [Related]

  • 18. Pilot clinical investigation of risperidone in the treatment of psychotic patients.
    Gelders YG, Heylen SL, Vanden Bussche G, Reyntjens AJ, Janssen PA.
    Pharmacopsychiatry; 1990 Sep 10; 23(5):206-11. PubMed ID: 1701262
    [Abstract] [Full Text] [Related]

  • 19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
    Arch Gen Psychiatry; 2003 Jul 10; 60(7):681-90. PubMed ID: 12860772
    [Abstract] [Full Text] [Related]

  • 20. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
    Min SK, Rhee CS, Kim CE, Kang DY.
    Yonsei Med J; 1993 Jun 10; 34(2):179-90. PubMed ID: 7691017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.